Two “real promise” techs join near misses of NICE medtech programme
This article was originally published in Clinica
Executive Summary
Two technologies have fallen foul of the UK National Institute for Health and Clinical Excellence’s (NICE) standards of clinical and cost-effectiveness evidence. They are Celleration's MIST Therapy wound-healing device and Ambicare Health's Ambulight PDT (photodynamic therapy) device for skin cancer.